This is not the latest version of this item. The latest version can be found here.
Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction
Name
1-s2.0-S2452302X21002059-main.pdf
Description
Published version
Size
2.72 MB
Format
Adobe PDF
Checksum (MD5)
783a67f3369cee3d3f51732b487a14dd
Author(s)
Rosalia, Luca
Ozturk, Caglar
Shoar, Saeed
Fan, Yiling
Malone, Grainne
Cheema, Faisal H
Conway, Claire
Byrne, Robert A
Duffy, Garry P
Malone, Andrew
Date Issued
2021
Journal
JACC: Basic to Translational Science
Publisher
Elsevier BV
Citation
Rosalia, Luca, Ozturk, Caglar, Shoar, Saeed, Fan, Yiling, Malone, Grainne et al. 2021. "Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction." JACC: Basic to Translational Science, 6 (9-10).
Version
Final published version
Abstract
Characterized by a rapidly increasing prevalence, elevated mortality and rehospitalization rates, and inadequacy of pharmaceutical therapies, heart failure with preserved ejection fraction (HFpEF) has motivated the widespread development of device-based solutions. HFpEF is a multifactorial disease of various etiologies and phenotypes, distinguished by diminished ventricular compliance, diastolic dysfunction, and symptoms of heart failure despite a normal ejection performance; these symptoms include pulmonary hypertension, limited cardiac reserve, autonomic imbalance, and exercise intolerance. Several types of atrial shunts, left ventricular expanders, stimulation-based therapies, and mechanical circulatory support devices are currently under development aiming to target one or more of these symptoms by addressing the associated mechanical or hemodynamic hallmarks. Although the majority of these solutions have shown promising results in clinical or preclinical studies, no device-based therapy has yet been approved for the treatment of patients with HFpEF. The purpose of this review is to discuss the rationale behind each of these devices and the findings from the initial testing phases, as well as the limitations and challenges associated with their clinical translation.
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
10.1016/J.JACBTS.2021.06.002
